The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma
Official Title: Study on the Safety and Effectiveness of NRT6003 Injection in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Study ID: NCT06310590
Brief Summary: The goal of this clinical trial is to evaluate the safety and efficacy of NRT6003 Injection in patients with unresectable HCC.
Detailed Description: The efficacy and safety of Yttrium-90 carbon microspheres in patients with unresectable HCC remain unknown. This trial is a prospective, multicenter, open-label, single-arm phase I trial designed to evaluate the safety and efficacy of NRT6003 injection. The primary objective is to evaluate the safety of NRT6003 Injection. While the secondary objectives include the assessments of the antitumoral efficacy, the improvement of patients´ quality of life, and the distribution characteristics of Yttrium-90 in body.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Anhui Provincial Hospital, Hefei, Anhui, China
Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Hunan Provincial People's Hospital, Changsha, Hunan, China
Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
The Southwest Hospital of Army Medical University, Chongqing, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
The First Affiliated Hospital of Naval Medical University, Shanghai, , China
The Third Affiliated Hospital of Naval Medical University, Shanghai, , China
Zhongshan Hospital, Fudan University, Shanghai, , China
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, , China
Name: Gaojun Teng, MD
Affiliation: Zhongda Hospital
Role: PRINCIPAL_INVESTIGATOR